MONTE ROSA THERAPEUTICS INC
NASDAQ: GLUE (Monte Rosa Therapeutics, Inc.)
最近更新时间: 3小时之前10.76
-0.11 (-1.01%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Monte Rosa Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.2 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.0 |
| 相对估值 | NA |
| 财务健康 | -5.0 |
| 宏观环境 | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.01 |
|
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.73% |
| 机构持股比例 | 101.33% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Nea Management Company, Llc | 30 Jun 2026 | 7,692,298 |
| Montanova Capital, Llc | 30 Jun 2026 | 3,549,539 |
| Versant Venture Management, Llc | 30 Jun 2026 | 3,180,780 |
| Braidwell Lp | 30 Jun 2026 | 2,451,562 |
该时间范围内无数据。
投资组合